Thomas Bailard is the co-founder and current manager of Bailard Inc. Located in California, Bailard uses quantitative and fundamental analyses to choose its investments. In its latest 13F filing, Bailard Inc. has disclosed a total of 235 positions as of the end of the second quarter of 2014. The value of the fund’s equity portfolio amounted to $650.1 million, up from $630.5 million reported as at the end of the previous quarter.
From the Bailard’s equity portfolio, we have picked top five holdings, in term of value. The first on the list is Apple Inc. (NASDAQ:AAPL), in which the fund boosted its position to 84,196 shares, worth $7.82 million, from 9,142 shares. For its fiscal 2014 third quarter ended June 28, 2014, Apple Inc. (NASDAQ:AAPL) reported revenue of $37.4 billion, compared to $35.3 billion in the year-ago quarter. Its quarterly net profit was $7.7 billion, or $1.28 per diluted share, compared to net profit of $6.9 billion, or $1.07 per diluted share, in the same quarter of 2013. Among other shareholders of Apple Inc. (NASDAQ:AAPL) include David Einhorn‘s Greenlight Capital and Natixis Global Asset Management‘s Harris Associates, holding 1.99 million shares and 1.56 million shares, respectively.
Bailard revealed upping its stake in BioDelivery Sciences International Inc. (NASDAQ:BDSI) to 398,000 shares, with a reported value of $4.80 million. Previously, the fund reported ownership of 342,400 shares of the company. BioDelivery Sciences International Inc. (NASDAQ:BDSI) is a specialty pharmaceutical company focusing in the areas of pain management and addiction medicine, has a market cap of $622.01 million. Aside from Bailard, Deerfield Management, led by James E. Flynn, owns 3.99 million shares of BioDelivery Sciences International Inc. (NASDAQ:BDSI) and Kevin Kotler’s Broadfin Capital holds 3.47 million shares.
The third position is held by Johnson & Johnson (NYSE:JNJ), in which the fund disclosed a $4.36 million stake, which contains 41,638 shares. The stake represents an increase from 39,373 the fund held previously. Recently, Johnson & Johnson (NYSE:JNJ), which is engaged in the research and development and sale of health care products, announced that its board of directors approved the repurchase of up to $5 billion of the company’s common stock. Other significant shareholders of Johnson & Johnson (NYSE:JNJ) include Ken Fisher’s Fisher Asset Management, owning 9.98 million shares, and Donald Yacktman’s Yacktman Asset Management, holding 9.57 million shares of the company.
In Chevron Corporation (NYSE:CVX), Bailard disclosed holding 30,575 shares, with a reported value of $3.99 million. The stake is up from 29,138 the fund held earlier. Chevron Corporation (NYSE:CVX) is an integrated energy company having a market cap of $248.60 billion. Last month, the company’s subsidiary Chevron Global Energy Inc. announced the sale of its 25% non-operated interest in a producing oil concession in southern Chad and the related export pipeline interests to the Republic of Chad for about $1.3 billion. In addition to Bailard, other shareholders of the company include Ken Fisher’s Fisher Asset Management, owning 3.50 million shares, according to our record. Another investor, Adage Capital Management, managed by Phill Gross and Robert Atchinson, revealed owning 2.73 million shares of Chevron Corporation (NYSE:CVX).
On the fifth spot is Enanta Pharmaceuticals Inc. (NASDAQ:ENTA), in which the fund increased its position to 91,500 shares, worth $3.94 million, from 74,306 shares. Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) is a research and development-focused biotechnology company. For the fiscal second quarter ended March 31, 2014, the company reported revenue of $2.2 million, compared to $1.2 million for the same period of 2013. It reported a net loss of $5.2 million, compared to a net loss of $3.7 million for the same quarter last year. The shareholders of the company, in addition to Bailard, include Peter Kolchinsky’s RA Capital Management and Mitchell Blutt’s Consonance Capital Management, holding 1.54 million and 1.25 million shares of the company, respectively.
Disclosure: none
